Systemic Cysteine Elevation Sustains T-Cell Activation to Potentiate PD-1 Blockade

Area of Science:

• Immunology
• Microbiome research
• Cancer biology

Background:

• Immune checkpoint inhibitors (ICIs) like anti-PD-1 therapy show limited efficacy in pancreatic cancer.
• Resistance to anti-PD-1 therapy is a significant challenge in treating pancreatic ductal adenocarcinoma.

Purpose of the Study:

• To investigate the potential of probiotics to overcome resistance to anti-PD-1 therapy in pancreatic cancer.
• To elucidate the underlying mechanisms, particularly metabolic pathways, involved in restoring immunotherapy sensitivity.

Main Methods:

• Utilized pancreatic cancer mouse models treated with anti-PD-1 therapy alone or in combination with probiotics.
• Analyzed tumor control, microbial pathways, serum and intratumoral metabolite levels (cysteine), and T cell function.
• Assessed the impact of oral cysteine supplementation on anti-PD-1 therapy efficacy.

Main Results:

• Concurrent administration of probiotics with anti-PD-1 therapy led to robust tumor control in mice.
• This combination therapy was associated with enriched microbial cysteine biosynthesis pathways and elevated serum cysteine levels.
• Serum cysteine levels inversely correlated with tumor burden and were found to directly promote T cell survival, activation, and cytotoxicity.
• Oral cysteine supplementation mimicked the immune-restorative effects of probiotics, synergizing with anti-PD-1 therapy.

Conclusions:

• Probiotics can restore sensitivity to anti-PD-1 therapy in pancreatic cancer by modulating systemic cysteine availability.
• Systemic cysteine is a critical factor for T cell function and a potential metabolic target to enhance cancer immunotherapy.
• Targeting cysteine metabolism presents a promising strategy to improve treatment outcomes for pancreatic cancer patients resistant to ICIs.